A melanoma lawsuit is a medical malpractice claim brought when a doctor fails to diagnose, misdiagnoses, or delays the diagnosis of melanoma and the patient’s cancer advances as a result. These cases are the most common type of skin cancer malpractice claim, accounting for roughly half of all such litigation, and they have produced settlements and verdicts ranging from tens of thousands of dollars to more than $9 million. They are also hard to win: defendants prevail more often than plaintiffs, and the difference between a winning case and a losing one usually comes down to whether the plaintiff can show that catching the cancer earlier would have changed the outcome.
Melanoma generates so much litigation for two reasons. It is common enough that most physicians will see it, and it is difficult enough to diagnose that errors happen often. Roughly 30 percent of melanoma cases are initially misdiagnosed, according to research cited in the Journal of the American Academy of Dermatology. And the disease punishes delay: a one-month wait for treatment at stage one raises the risk of death by five percent, with the risk climbing steeply from there.
What Plaintiffs Typically Allege
A 2026 study by Barnawi and colleagues, which reviewed 188 skin cancer malpractice cases going back to 1930, found that failure or delay in diagnosis was the leading allegation, appearing in 38.1 percent of cases. Treatment or management errors accounted for 24.2 percent, outright misdiagnosis for 11.4 percent, “deliberate indifference” (typically in prison healthcare settings) for 8.3 percent, inadequate informed consent for 7.5 percent, and pathology errors for 7.2 percent.
A separate 2026 analysis by Ribaudo and colleagues looked only at melanoma cases from 2000 to 2024 and only at cases plaintiffs won. In those 34 wins, three allegations tied for most common at 21 percent each: failure to test or diagnose, false-negative histopathology (a pathologist misreading a biopsy slide as benign when it was cancer), and negligent follow-up.
The recurring fact patterns behind those allegations tend to look like this:
- A physician sees a suspicious mole with atypical features but recommends watching it rather than biopsying it, or does not communicate to the patient or a referring doctor that a biopsy is needed.
- A biopsy is taken but the pathologist reads the slide as benign when the tissue actually shows melanoma, and the patient is sent home untreated.
- A concerning lesion is identified but no system ensures the patient comes back, and the cancer progresses in the gap.
- A melanoma is mistaken for a wart, cyst, eczema, psoriasis, or another benign condition, delaying the correct workup.
Who Gets Named as a Defendant
The defendants are not always dermatologists. In the Barnawi dataset, family physicians were the most frequently named defendants at 27.5 percent, dermatologists came in at 20.1 percent, and pathologists or dermatopathologists at 14.4 percent. The Ribaudo study found that 85 percent of defendants in cases plaintiffs won were non-dermatologists; prison medical staff were the single largest group at 22 percent, with dermatologists second at 19 percent.
Pathologists play an outsized role in the cases plaintiffs actually win. Ribaudo found pathologists were the most common specialty in plaintiff victories, appearing in 24 percent of those outcomes. Reading a biopsy slide is inherently subjective, disagreements between competent pathologists are common, and courts scrutinize that step closely because it is the definitive moment of diagnosis.
What a Plaintiff Has to Prove
Winning a melanoma malpractice case requires proving four things: that a doctor-patient relationship existed, that the physician’s conduct fell below the accepted standard of care, that the breach directly caused the patient’s injury, and that the patient suffered compensable damages. Each of those elements almost always requires expert testimony from a physician in the same specialty as the defendant.
Causation is where these cases live or die. Defendants routinely argue that the melanoma had already progressed or metastasized before the alleged error, so the outcome would have been the same either way. In the Ribaudo study, every single case decided for the plaintiff turned on evidence of causation — proof that earlier diagnosis would have changed the prognosis. Oncologists establish this by pointing to stage-specific survival statistics: a stage one melanoma is highly curable, a stage four melanoma often is not, and the delay is what pushed the patient from one category to the other.
How Often Plaintiffs Win
Defendants win more often. Barnawi reported defense verdicts in 55 percent of closed cases and plaintiff verdicts in just 5.5 percent, with the rest settled or otherwise resolved. Ribaudo found a 60 percent defendant win rate against a 34 percent plaintiff win rate. An earlier 2017 study by Rayess and colleagues, looking at 80 melanoma cases over 20 years, found 49 percent went to defendants. That study also found that whether the patient died did not significantly affect whether a payment was made or how large it was, a counterintuitive result that likely reflects how difficult causation is to prove even in fatal cases.
One finding from the Ribaudo study is worth pausing on: more than half of the defense wins came on procedural or technical grounds rather than on the merits. Expired statutes of limitations, improper service, and statutes of repose accounted for the majority. Only 43 percent of defense wins came from the plaintiff failing to prove negligence or causation. Filing deadlines, in other words, decide a lot of these cases before a jury ever hears the medicine.
What Melanoma Cases Have Been Worth
Payouts vary widely with the patient’s age, the length of the delay, the severity of the harm, and the state’s rules on damages. Average payouts in failure-to-diagnose cancer cases have been estimated at between $400,000 and $700,000, but individual results run from six figures to eight.
Lockshin v. Semsker
Richard Semsker, a 44-year-old Maryland attorney, had a 6mm mole on his back noted by his dermatologist during a 1998 checkup, but the mole was never removed. A miscommunication left each physician believing the other had handled the excision. Years later a different doctor examined the mole, then 1.3 centimeters, and concluded it was benign without removing it. By the time it was finally excised in 2006, it was metastatic malignant melanoma. Semsker died in October 2007. A jury awarded his estate $5,805,000, including $3 million in non-economic damages. The Maryland Court of Appeals ruled that the state’s statutory cap on non-economic damages applied and had to be calculated before any reduction for a separate $1 million settlement with another defendant.
A $4.35 Million Ohio Settlement
A 42-year-old father of three in Ohio had a shave biopsy of a mole on his right forearm in 2015. A dermatopathologist read the tissue as benign; it was actually early stage one melanoma. The misread cost him three and a half years. By the time the correct diagnosis came in 2018, the cancer was stage four, and he died within six months. The wrongful death case, filed in Summit County, settled for $4.35 million in November 2019.
A $1 Million Massachusetts Settlement
A 55-year-old man had a back lesion removed in August 2001. The initial pathology called it benign, but a second opinion could not rule out melanoma and recommended re-excision with clear margins. The dermatologist performed the re-excision, but documentation did not confirm that the recommended margins were obtained, and the follow-up pathology showed only scar tissue. A year later a recurrent lesion at the same site was diagnosed as severely atypical, and further surgery confirmed stage IIIA melanoma with lymph node metastasis. The patient died in March 2009. The case settled for $1 million the week before the February 2010 trial.
Other Reported Outcomes
Reported results have included a $9.3 million Colorado verdict in 2013, a $5.7 million California verdict in 2024, an $8.5 million California settlement involving a dermatologist who failed to biopsy a mole that turned out to be melanoma with liver and lung metastases, and a $6 million South Carolina settlement in 2018. At the other end, settlements of $150,000 to $300,000 have been recorded in cases with less severe outcomes or weaker causation evidence.
What You Can Recover
Damages come in two main buckets. Economic damages cover quantifiable losses: past and future medical bills, lost wages, lost earning capacity, additional care costs, and funeral expenses in wrongful death cases. Non-economic damages compensate for pain and suffering, emotional distress, disfigurement, disability, loss of enjoyment of life, and loss of consortium.
Punitive damages exist in theory but are rare in medical malpractice. They generally require evidence of intentional misconduct rather than ordinary negligence, and across all malpractice categories they appear in fewer than 1.5 percent of verdicts.
How much you can actually recover for non-economic damages depends heavily on where the case is filed. About half the states cap non-economic damages in malpractice cases. California has historically capped them at $250,000 under its MICRA statute. Maryland’s cap, which drove the appeal in Lockshin, was $725,000 as of 2014 with $15,000 annual increases. New York, Pennsylvania, and New Jersey have no caps on non-economic damages, which is part of why some of the largest melanoma verdicts have come from those states.
How Long You Have to File
Every state sets a deadline for filing a malpractice suit, generally one to three years. The harder question in a melanoma case is when the clock starts, because a patient often has no way of knowing a biopsy was misread until the cancer resurfaces years later.
Many states apply a “discovery rule” that delays the start of the limitations period until the patient knew or reasonably should have known about the potential malpractice. New York went further with “Lavern’s Law,” signed by Governor Andrew Cuomo on January 31, 2018. In cancer misdiagnosis cases, the statute of limitations now starts when the patient discovers or reasonably should have discovered the misdiagnosis, and the patient then has two and a half years to file, subject to a seven-year outer cap from the original malpractice. Before the law, the standard 30-month clock ran from the negligent act itself, and patients whose biopsies were misread frequently ran out of time before they knew anything was wrong.
Other states are less forgiving. California sets a one-year-from-discovery deadline with a three-year outer limit. Arkansas generally does not apply a discovery rule outside narrow situations such as a foreign object left in the body. Given how many defense wins in melanoma cases come from expired deadlines, the specific rule in your state is often the first thing to check.
A Note on AI Diagnostic Tools
Artificial intelligence is starting to appear in melanoma diagnosis. A meta-analysis published in JAMA Dermatology in April 2026 found AI systems reached about 81 percent sensitivity and 76 percent specificity for melanoma detection, roughly matching dermatologist performance, with one study showing sensitivity climbing to nearly 92 percent when clinicians used AI as decision support. In February 2025, an AI system called DERM received a Class III CE mark in the EU, becoming the first autonomous AI system authorized to triage skin cancer without clinician oversight.
As of late 2025, no documented U.S. malpractice case had turned on an AI diagnostic error, according to The Doctors Company. That is likely to change. The American Law Institute approved a new restatement of medical malpractice law in May 2024 that shifts the framework toward patient-centered “reasonable care” rather than strict adherence to customary practice, which could make it easier to argue that failing to use available AI tools breaches the standard. California’s Assembly Bill 2013, effective January 1, 2026, requires disclosures about AI training data and use cases. If you are evaluating a case involving an AI-assisted or AI-driven diagnosis, this is an unsettled area, and the answers may depend on rules that did not exist a year earlier.